Accusations fly over ‘integrity’ of Lancet hydroxychloroquine study
Australian researchers, including Professor Allen Cheng, demand to know how the data for the study was gathered
Leading infectious diseases clinicians have sounded the alarm over an observational study that prompted the WHO to suspend its trial of hydroxychloroquine treatment for COVID-19.
Last month, the Lancet published a multinational registry analysis of data showing the drug had no therapeutic benefit against the illness and increased the risk of death by 35-45%.
